BN Business News
Add your company to Business Communicator →

Business · 22/09/2021Updated: 10/17/2026 · 1 min read

B. Braun Medical, Inc. Seeks Withdrawal of FDA Approval for Hydroxyethyl Starch Injection

Summary

The FDA is withdrawing approval of an abbreviated new drug application for 6 Percent Hydroxyethyl Starch 130/0.4 in 0.9 Percent Sodium Chloride Injection, submitted by B. Braun Medical, Inc., due to the drug no longer being marketed and the company's request to waive a hearing.

Original source language: Federal Register — Food and Drug AdministrationOpen original release →

Explore insights

Business insights →